| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 364,937 | 398,964 |
| Net (decrease) increase in cash and cash equivalents | -164,206 | -119,789 |
| Cash and cash equivalents at beginning of period | 340,238 | - |
| Cash and cash equivalents at end of period | 176,032 | - |
Akero Therapeutics, Inc. (AKRO)
Akero Therapeutics, Inc. (AKRO)